GRI Bio, Inc.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for inflammatory, fibrotic, and autoimmune diseases. The company's core mission is to fundamentally change the treatment landscape for these conditions by targeting Natural Killer T (NKT) cells, which are crucial regulators early in the inflammatory cascade. Headquartered in La Jolla, California, GRI Bio, Inc. was founded in 2009.

GRI Bio's pipeline includes its lead program, GRI-0621, an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells, which is currently in Phase IIa clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Additionally, the company is advancing GRI-0803, a novel oral agonist of type 2 Natural Killer T (NKT) cells, through preclinical development for autoimmune disorders such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The company also maintains a proprietary library of over 500 compounds to fuel its ongoing research and development efforts.

Led by President, CEO, and Director Marc Hertz, PhD, GRI Bio, Inc. is publicly traded on NASDAQ under the ticker symbol GRI. In May 2026, the company reported its first-quarter financial results and presented new data reinforcing the differentiated profile of GRI-0621 in idiopathic pulmonary fibrosis. Earlier in April 2026, GRI Bio received a Notice of Allowance for a UAE patent application related to novel Type 2 Diverse NKT Cell Agonists for inflammatory conditions, further strengthening its intellectual property portfolio.